Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

NCT03781167 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03781167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03781167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2019
Completion date
August 17, 2022
Enrollment
244 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease (pd)